BIOGEN INC. Debt Securities, Available-for-sale, Amortized Cost
BIOGEN INC. (BIIB) had Debt Securities, Available-for-sale, Amortized Cost of $1.37 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-04-29
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.37B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.24B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $97.60M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $4.69B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-03-31 | $1.37B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $1.24B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $97.60M 10-Q · filed 2025-10-30 |
| 2023-06-30 | $4.69B 10-Q · filed 2023-07-25 |
| 2023-03-31 | $3.13B 10-Q · filed 2023-04-25 |
| 2022-12-31 | $2.20B 10-K · filed 2024-02-14 |
| 2022-09-30 | $2.12B 10-Q · filed 2022-10-25 |
| 2022-06-30 | $3.28B 10-Q · filed 2022-07-20 |
| 2022-03-31 | $3.02B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $2.44B 10-K · filed 2023-02-15 |
| 2021-09-30 | $2.38B 10-Q · filed 2021-10-20 |
| 2021-06-30 | $2.22B 10-Q · filed 2021-07-22 |
| 2021-03-31 | $2.14B 10-Q · filed 2021-04-22 |
| 2020-12-31 | $2.05B 10-K · filed 2022-02-03 |
| 2020-09-30 | $2.36B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $2.86B 10-Q · filed 2020-07-22 |
| 2020-03-31 | $2.25B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $2.96B 10-K · filed 2021-02-03 |
| 2019-09-30 | $3.90B 10-Q · filed 2019-10-22 |
| 2019-06-30 | $2.53B 10-Q · filed 2019-07-24 |
| 2019-03-31 | $3.04B 10-Q · filed 2019-04-24 |
| 2018-12-31 | $3.69B 10-K · filed 2020-02-06 |
| 2018-09-30 | $3.29B 10-Q · filed 2018-10-23 |
| 2018-06-30 | $3.14B 10-Q · filed 2018-07-24 |
| 2018-03-31 | $3.01B 10-Q · filed 2018-04-24 |
| 2017-12-31 | $5.17B 10-K · filed 2019-02-06 |
| 2017-09-30 | $5.03B 10-Q · filed 2017-10-24 |
| 2017-06-30 | $4.36B 10-Q · filed 2017-07-25 |
| 2017-03-31 | $4.79B 10-Q · filed 2017-04-25 |
| 2016-12-31 | $5.41B 10-K · filed 2018-02-01 |
| 2016-09-30 | $5.32B 10-Q · filed 2016-10-26 |
| 2016-06-30 | $5.90B 10-Q · filed 2016-07-21 |
| 2016-03-31 | $5.64B 10-Q · filed 2016-04-21 |
| 2015-12-31 | $4.89B 10-K · filed 2017-02-02 |
| 2015-09-30 | $3.70B 10-Q · filed 2015-10-21 |
| 2015-06-30 | $3.19B 10-Q · filed 2015-07-24 |
| 2015-03-31 | $2.05B 10-Q · filed 2015-04-24 |
| 2014-12-31 | $2.11B 10-K · filed 2016-02-03 |
| 2014-09-30 | $2.05B 10-Q · filed 2014-10-22 |
| 2014-06-30 | $1.72B 10-Q · filed 2014-07-23 |
| 2013-12-31 | $1.25B 10-K · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |